A Cohort Study of Operationally Tolerant Allograft Recipients
Principal Investigator
Sindhu Chandran | Immune Tolerance Network | San Francisco, CA
Locations
Ann & Robert H. Lurie Children's Memorial Hospital of Chicago: Pediatric Transplantation | Chicago,IL
Emory University School of Medicine: Transplantation | Atlanta,GA
UCSF School of Medicine: Transplantation | San Francisco,CA
University of Pennsylvania Medical Center: Transplantation | Philadelphia,PA
Children’s Hospital of Pittsburgh of UPMC Peds Transplant | Pittsburgh,PA
Study Code
ITN063ST
Study Status
Complete
Abstract
For organ transplant recipients, anti-rejection medications known as “immunosuppressive drugs” help prevent the immune system from attacking the foreign organ and causing damage. Although this helps keep the organ healthy, anti-rejection medications have a number of serious side effects including an increased risk of infections and certain kinds of cancer.
Some individuals who receive organ transplants are able to come off of all immune-suppressing medications without rejecting their organ. This is called “tolerance.”
The goal of the ALLTOL Study is to follow tolerant transplant recipients to learn:
- How long liver or kidney transplant recipients can remain tolerant
- What happens in the tolerant recipient’s body over time
- If there are patterns in the body that are linked to tolerance
